MedPage Today on MSN

First drug for deadly transplant complication gets FDA's blessing

The FDA has approved narsoplimab (Yartemlea) as the first treatment for hematopoietic stem cell transplant (HSCT)-associated ...

FDA Approves Omeros’ YARTEMLEA® – First and Only Therapy Indicated for TA-TMA

Omeros Corporation (NASDAQ: OMER) today announced that the U.S. Food and Drug Administration (FDA) has approved YARTEMLEA® ...
Stocks Telegraph

Omeros Corporation (OMER) 72.11% in Intraday Trading: FDA Approves Yartemlea, Driving Surge

Summary • Omeros Corporation’s stock jumped 72.1% to $15.06 following FDA approval of Yartemlea, its therapy for TA-TMA.• Yartemlea is the first therapy targeting hematopoietic stem cell ...
Zacks Investment Research on MSN

Omeros gets FDA approval for YARTEMLEA as first therapy for TA-TMA

Omeros Corporation OMER recently announced that the FDA approved its YARTEMLEA (narsoplimab-wuug) to treat hematopoietic stem ...